Cosmos Health Q3 revenue rises to record high on contract manufacturing
COSM•Cosmos Health’s preliminary Q3 revenue rose 2% year over year to a record $17.4 million, below the $20.89 million estimate from one analyst. The company reaffirmed its full-year 2026 revenue outlook of more than $90 million and expects Q4 to be its strongest quarter.
1. Revenue and outlook
Preliminary Q3 revenue rose 2% year over year to a company record of $17.4 million, compared with a $20.89 million estimate from one analyst. Cosmos Health reaffirmed that full-year 2026 revenue will surpass $90 million and expects Q4 2026 to be its strongest quarter, driven by contract manufacturing and US sales.
2. Growth drivers
The company said a record production pipeline at Cana Laboratories, record distribution volumes at CosmoFarm, and growth in proprietary brands drove the revenue increase. Proprietary brands expanded into new territories and had building sales momentum in the US.
